Company intelligence / Profile preview

ESP Pharmaceuticals

Edison, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

ESP Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of products for the acute care hospital market. The company's portfolio primarily targeted cardiovascular and oncology indications, featuring key products such as Cardene I.V. for hypertension and Retavase for acute myocardial infarction. Founded in 2002, ESP Pharmaceuticals quickly established a commercial presence before being acquired by PDL BioPharma in 2005. The acquisition was driven by ESP's strong sales force and its established revenue-generating products which complemented PDL's pipeline.

Therapeutic areas: OncologyCardiovascular
Modalities: Small moleculeRecombinant proteinProtein
Industry: Biotech

Partnerships

CentocorWyeth

Beyond the preview

Go deeper on ESP Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESP Pharmaceuticals.

Explore the full profile